clofazimine has been researched along with pa 824 in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 5 (35.71) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Aínsa, JA; Martín, C; Ramón-García, S; Thompson, CJ | 1 |
| Barry, CE; Dartois, V | 1 |
| Dufková, I; Hrabálek, A; Karabanovich, G; Klimešová, V; Němeček, J; Pávek, P; Roh, J; Smutný, T; Stolaříková, J; Vávrová, K; Vejsová, M; Vicherek, P | 1 |
| Biava, M; Cocozza, M; Consalvi, S; Poce, G | 1 |
| Dušek, J; Hrabálek, A; Huszár, S; Jand'ourek, O; Karabanovich, G; Klimešová, V; Kočová Vlčková, H; Konečná, K; Konyariková, Z; Korábečný, J; Korduláková, J; Kučera, T; Mikušová, K; Pávek, P; Pávková, I; Pavliš, O; Roh, J; Savková, K; Stolaříková, J; Vávrová, K | 1 |
| Ekins, S; Kyaw Zin, PP; Makarov, V; Reynolds, RC; Salina, E | 1 |
| Amoabeng, O; Mdluli, KE; Minkowski, A; Nuermberger, EL; Tasneen, R; Upton, AM; Williams, K | 1 |
| Burger, DA; Dawson, R; Diacon, AH; Donald, PR; Everitt, D; Hutchings, J; Mendel, CM; Schall, R; Symons, G; van Niekerk, C; Venter, A; von Groote-Bidlingmaier, F | 1 |
| Laughon, BE; Lee, SFK; Lipman, M; McHugh, TD | 1 |
| Farhat, M; Kadura, S; King, N; Köser, CU; Nakhoul, M; Theron, G; Zhu, H | 1 |
| Almoslem, M; Drusano, GL; Duncanson, B; Kim, S; Louie, A; Myrick, J; Neely, M; Nole, J; Peloquin, CA; Scanga, CA; Schmidt, S; Yamada, W | 1 |
| Chen, X; Fu, L; Lu, Y; Qi, X; Wang, B; Wang, H; Zhang, W; Zheng, L | 1 |
| Fitzgibbon, MM; Flanagan, PR; Mok, S; Roycroft, E; Wagener, J | 1 |
5 review(s) available for clofazimine and pa 824
| Article | Year |
|---|---|
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Lung; Mycobacterium tuberculosis; Tuberculosis | 2013 |
SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
Topics: Animals; Antitubercular Agents; Humans; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Molecule Property Analyses of Active Compounds for
Topics: Antitubercular Agents; Bacterial Proteins; Drug Discovery; Drug Resistance, Bacterial; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Nucleoside-Phosphate Kinase; Structure-Activity Relationship; Tuberculosis | 2020 |
New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease.
Topics: Amikacin; Anti-Bacterial Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Liposomes; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Oxazoles | 2019 |
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Linezolid; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pharmaceutical Preparations; Tuberculosis, Multidrug-Resistant | 2020 |
1 trial(s) available for clofazimine and pa 824
| Article | Year |
|---|---|
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nitroimidazoles; Pyrazinamide; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2015 |
8 other study(ies) available for clofazimine and pa 824
| Article | Year |
|---|---|
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
Topics: Antitubercular Agents; Bacterial Proteins; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Clofazimine; Dithiothreitol; Drug Resistance, Multiple, Bacterial; Gene Expression Regulation, Bacterial; Glutathione; Hydrogen Peroxide; Membrane Transport Proteins; Mutation; Mycobacterium tuberculosis; Oligonucleotide Array Sequence Analysis; Oxidative Stress; Rifampin; Valinomycin | 2009 |
1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.
Topics: Antineoplastic Agents; Antitubercular Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; HeLa Cells; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitrobenzenes; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured | 2014 |
Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
Topics: Alcohol Oxidoreductases; Antitubercular Agents; Bacterial Proteins; Dinitrobenzenes; Dose-Response Relationship, Drug; Drug Development; Hydrocarbons, Fluorinated; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Triazoles | 2019 |
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Pyrazinamide; Random Allocation; Tuberculosis | 2015 |
Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2022 |
Efficacy of PBTZ169 and pretomanid against Mycobacterium avium,
Topics: Animals; Anti-Bacterial Agents; Clofazimine; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium abscessus; Mycobacterium avium; Mycobacterium chelonae; Mycobacterium fortuitum; Mycobacterium Infections; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Rifabutin | 2023 |
Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Genomics; Humans; Linezolid; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant | 2023 |